Podcasts about Lymphoma

Today, on Karl and Crew, we kicked off the week with discussions about a cancer patient ministry with Phil Zielke and how to make the most of a screen-free summer with your kids, with Arlene Pellicane. First, Phil Zielke joined us to share his testimony of how he drew near to God when he was diagnosed with Stage 4B Hodgkin’s Lymphoma, and then how God placed it on his heart to start a ministry that serves cancer patients. Phil’s Friends is a ministry that provides Christ-centered support and hope to those affected by cancer. Then we had Arlene Pellicane join us to talk about the importance of parents connecting with their children by limiting their screen time. Arlene is a speaker, author, and host of the Happy Home podcast. She is also a marriage and parenting expert. Arlene has also authored several books, including “Screen Kids.” We then discussed our need for God’s grace. We were born into sin, so it is in our nature to be sinful, but when we are born again through Christ, we are renewed by God’s grace. Romans 7:18-25 affirms this, as Paul tells us that sin dwells within us and affects how we move and think without God. Only God can deliver us from sin through Jesus Christ. We also heard updates from Karl, who was broadcasting remotely from the Maranatha Bible Missionary Conference, Vacation and Retreat Center. Dr. Josh Stephens joined Karl to discuss the sovereignty and providence of God as shown throughout the book of Ruth. Dr. Stephens is the Lead Pastor of Cape Bible Church in Missouri and is also the founder and executive director of the Biblical Counseling Alliance. You can hear the highlights of today's program on the Karl and Crew Showcast. If you're looking to hear a particular segment from the show, look at the following time stamps: Gospel (Need for God) [ 05:55-17:30 ] Phil Zielke Interview (Phil's Friends Ministry) [ 44:25-55:18 ] Arlene Pellicane Interview [ 55:28-01:06:34 ] Dr. Josh Stephens (Book of Ruth breakdown) [ 30:50-43:50 ]Donate to Moody Radio: http://moodyradio.org/donateto/morningshowSee omnystudio.com/listener for privacy information.

Today, on Karl and Crew, we kicked off the week with discussions about a cancer patient ministry with Phil Zielke and how to make the most of a screen-free summer with your kids, with Arlene Pellicane. First, Phil Zielke joined us to share his testimony of how he drew near to God when he was diagnosed with Stage 4B Hodgkin’s Lymphoma, and then how God placed it on his heart to start a ministry that serves cancer patients. Phil’s Friends is a ministry that provides Christ-centered support and hope to those affected by cancer. Then we had Arlene Pellicane join us to talk about the importance of parents connecting with their children by limiting their screen time. Arlene is a speaker, author, and host of the Happy Home podcast. She is also a marriage and parenting expert. Arlene has also authored several books, including “Screen Kids.” We then discussed our need for God’s grace. We were born into sin, so it is in our nature to be sinful, but when we are born again through Christ, we are renewed by God’s grace. Romans 7:18-25 affirms this, as Paul tells us that sin dwells within us and affects how we move and think without God. Only God can deliver us from sin through Jesus Christ. We also heard updates from Karl, who was broadcasting remotely from the Maranatha Bible Missionary Conference, Vacation and Retreat Center. Dr. Josh Stephens joined Karl to discuss the sovereignty and providence of God as shown throughout the book of Ruth. Dr. Stephens is the Lead Pastor of Cape Bible Church in Missouri and is also the founder and executive director of the Biblical Counseling Alliance. You can hear the highlights of today's program on the Karl and Crew Showcast. If you're looking to hear a particular segment from the show, look at the following time stamps: Gospel (Need for God) [ 05:55-17:30 ] Phil Zielke Interview (Phil's Friends Ministry) [ 44:25-55:18 ] Arlene Pellicane Interview [ 55:28-01:06:34 ] Dr. Josh Stephens (Book of Ruth breakdown) [ 30:50-43:50 ]Donate to Moody Radio: http://moodyradio.org/donateto/morningshowSee omnystudio.com/listener for privacy information.

In this week's episode, we'll learn about rapid, high-sensitivity diagnostic assays for TTP, or thrombotic thrombocytopenic purpura, that can reduce unnecessary treatments. After that: enhancing PD-1 blockade in relapsed/refractory extranodal NK/T-cell lymphoma. In a single-arm, phase 2 study, combined CD38 and PD-1 inhibition demonstrated durable responses and manageable safety. Finally, a lymphoma horror story with a happy ending. CREBBP mutations create a zombie enzyme that competes with its wild-type counterparts. By enforcing CD40 signaling, a bispecific antibody overcomes this effect and induces lymphoma cell death.Featured Articles:Rapid ADAMTS13 activity assays for thrombotic thrombocytopenic purpura: a systematic review and meta-analysisEfficacy of combined CD38 and PD-1 inhibition with isatuximab and cemiplimab for relapsed/refractory NK/T-cell lymphomaBlunted CD40-responsive enhancer activation in CREBBP-mutant lymphomas can be restored by enforced CD4 T-cell engagement

Heather Lino's then 3 year old son James was given a double whammy in 2020 when he was first diagnosed with T Cell Acute Lymphoblastic Lymphoma in July, and then roughly one month into his treatment he was diagnosed with a Chromosomal disorder known as Ring 14 Syndrome. This disorder affects 200-250 people around the world. This affliction causes seizures and intellectual disabilities and can have other problems associated with it as well. James is now 8 years old and is living his best life possible. 

Originally aired in 2023, Molly Jacobson interviews Dr. Kim Agnew about the groundbreaking trials of Monepantel, a sheep dewormer repurposed as a potential treatment for canine lymphoma. Discover the science behind this innovative therapy, its potential to stabilize lymphoma, and how it compares to traditional treatments like chemotherapy and prednisone.  Key Topics:  What is Monepantel, and how was it discovered?  The mechanism behind Monepantel's ability to target cancer cells.  Early trial results: Quality of life and stability for dogs with B-cell lymphoma.  How Monepantel compares to prednisone and chemotherapy.  Insights into ongoing and future clinical trials.  How dog lovers can participate in studies.  Your Voice Matters!   If you have a question for our team, or if you want to share your own hopeful dog cancer story, we want to hear from you! Go to https://www.dogcancer.com/ask to submit your question or story, or call our Listener Line at +1 808-868-3200 to leave a question.   Related Videos:  https://www.youtube.com/watch?v=_92w6TTXM5c   https://www.youtube.com/watch?v=uAZrPM1X8ww   Related Links:  PharmAust Dog Lymphoma Clinical Trial: https://www.pharmaust.com/petdogtrial/  Chapters:  00:00 Introduction  00:30 Meet Dr. Kim Agnew and Monepantel Overview  01:15 The Origin of Monepantel: From Dewormer to Cancer Fighter  03:30 How Monepantel Targets Cancer Cells  07:00 Insights on Clinical Trials for Canine Lymphoma  09:30 Benefits of Monepantel: A Daily Pill for Dogs  12:00 Comparing Monepantel to Chemotherapy and Prednisone  14:45 Early Trial Results: Stabilizing Lymphoma in Dogs  18:30 Why Lymphoma Was Chosen for Trials  20:00 Potential for Treating Other Cancers in Dogs  23:15 How to Enroll Dogs in Clinical Trials  26:45 Side Effects and Safety of Monepantel  31:00 Future Trials and Research Goals  34:30 Closing Thoughts and Resources  33:55 Closing Remarks and Resources    Get to know Kim Agnew, BVSc: https://www.dogcancer.com/people/kim-agnew-bvsc/     For more details, articles, podcast episodes, and quality education, go to the episode page: https://www.dogcancer.com/podcast/   Learn more about your ad choices. Visit megaphone.fm/adchoices

In this podcast, Mimi shares her experience of being a carer. Her partner Roger, who is the keyboard player in the band The Cure, was diagnosed with diffuse large B-cell lymphoma in September 2023. Mimi talks about the difficult moments they shared as they waited for test results; a mix of anxiety and numbness. She shares how much sadness she felt as Roger went through chemotherapy and how ill he was. She also talks about how they coped with the side effects of treatment, like the impact steroids had and adjusting to hair loss. This was a time when she felt she had to remain strong and positive, even though inside she was feeling so much stress. Over this period, life for both Roger and Mimi was about going from one hospital appointment to the other as after chemotherapy, Roger was treated with radiotherapy. They both looked forward to the end of treatment, but once it had finished, she explains how it still took a while to re-establish life again.Lymphoma Voices is a series of podcasts for people living with lymphoma, and their family and friends. In each podcast, we are in conversation with an expert in their field, or someone who has been personally affected by lymphoma, who shares their thoughts and experiences.   Lymphoma Action is the only charity in the UK dedicated to supporting people affected by lymphoma. We are here to make sure that everyone affected by the condition receives the best possible information, support, treatment and care. Our services include a Freephone helpline, support group network, Buddy Service, medical information, conferences for those affected by lymphoma, and education and training for healthcare professionals. We would like to thank all of our incredible supporters whose generous donations enable us to offer all our essential support services free of charge. As an organisation we do not receive any government or NHS funding and so every penny received is truly valued. From everyone at Lymphoma Action and on behalf of those affected by lymphoma, thank you. For further information visit: www.lymphoma-action.org.uk 

In this week's episode we'll learn more about a novel mouse model that recapitulates many of the properties of human sickle cell SC disease; results from the induction phase of the risk-adapted MIDAS trial of isatuximab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed, transplant-eligible multiple myeloma; and a link between splicing factor mutations and competitive fitness in myelodysplastic syndrome stem cells.Featured articles:A novel mouse model of hemoglobin SC disease reveals mechanisms underlying beneficial effects of hydroxyureaIsatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trialCell-autonomous dysregulation of interferon signaling drives clonal expansion of SRSF2-mutant MDS stem/progenitor cells

What do you do whenever your doctor tells you you've been diagnosed with cancer? This is Pastor Tom Arnould. Several years ago I received such a call. My doctor told me that a biopsy I had received earlier that week had come back as lymphoma. It's a phone call I'll remember for the rest of my life. I'd like to share my journey with you.

Associate Professor Paolo Strati (Department of Lymphoma and Myeloma, and Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA) joins us to discuss the results of a multicentre, open-label, phase 1 clinical trial of off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy for patients with relapsed or refractory B-cell lymphoma.Read the full article:https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(25)00142-5/fulltext?dgcid=buzzsprout_icw_podcast_July_25_lanhaeContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv

VJHemOnc recently attended the 2025 ASCO Annual Meeting in Chicago, IL, where we gained insights into the latest advancements in... The post Key HemOnc updates from ASCO 2025: myeloma, lymphoma, MPNs, & more! appeared first on VJHemOnc.

NeshamaCast is off for the summer, gearing up for an engaging Season 3. But in the meantime, we're pleased to bring you this special bonus episode featuring NAJC's Vice President Rebecca Kamil, BCC. Rabbi Kamil serves as a chaplain for the CLL Society in the Minneapolis area. The CLL Society supports and advocates for cancer patients with chronic lymphocytic leukemia and small lymphocytic lymphoma. Rabbi Kamil recently appeared on CareCast, the podcast of the CLL Society. Rabbi Kamil has rabbinic ordination from Hebrew Union College-Jewish Institute of Religion and is a Board Certified Chaplain through NAJC. Neshamacast is grateful to Doreen Zetterlund and CareCast for allowing us to share this interview on the NeshamaCast feed.  About our host:Rabbi Edward Bernstein, BCC, is the producer and host of NeshamaCast. He serves as Chaplain at Boca Raton Regional Hospital of Baptist Health South Florida. He is a member of the Board of Neshama: Association of Jewish Chaplains. Prior to his chaplain career, he served as a pulpit rabbi in congregations in New Rochelle, NY; Beachwood, OH; and Boynton Beach, FL. He is also the host and producer of My Teacher Podcast: A Celebration of the People Who Shape Our Lives. NeshamaCast contributor Rabbi Katja Vehlow was ordained at the Jewish Theological Seminary and is Director of Jewish Life at Fordham University. She trained as a chaplain at Moses Maimonides Medical Center in New York. Previously, she served as Associate Professor of Religious Studies at University of South Carolina. A native German speaker, she is planning a forthcoming German-language podcast on the weekly Torah portion with a focus on pastoral care. NeshamaCast contributor Chaplain David Balto is a volunteer chaplain at Washington Hospital Center in Washington, D.C. and Western Correctional Insitution, Maryland's maximum security prison. He coordinated the annual National Bikur Cholim Conference. Support NeshamaCast and NAJC with a tax deductible donation to NAJC. Transcripts for this episode and other episodes of NeshamaCast are available at NeshamaCast.simplecast.com and are typically posted one week after an episode first airs. Theme Music is “A Niggun For Ki Anu Amecha,” written and performed by Reb-Cantor Lisa Levine. Please help others find the show by rating and reviewing the show on Apple Podcasts or other podcast providers. We welcome comments and suggestions for future programming at NeshamaCast@gmail.com. And be sure to follow NAJC on Facebook to learn more about Jewish spiritual care happening in our communities.

Dr. Iyad Alnahhas interviews Drs. Isaias Hernandez-Verdin and Agusti Alentorn about their recent manuscript entitled: "Gut microbiome modulates the outcome in primary central nervous system lymphoma patients undergoing chemotherapy: An ancillary study from the BLOCAGE trial", published online in Neuro-Oncology in March 2025   Link: https://academic.oup.com/neuro-oncology/advance-article/doi/10.1093/neuonc/noaf059/8058778

In this week's episode, we'll learn about using AI to assess transplant risk in myelofibrosis. In a step toward personalized medicine, researchers report on a machine learning model that identifies 25% of patients with poor outcomes. After that: preventing priapism in men with sickle cell anemia. A recent phase 2 feasibility study shows high rates of recruitment, retention, and adherence to oral therapies, coupled with a significant reduction in the risk of this difficult complication. Finally, new research indicates that hallmarks of terminal T-cell exhaustion are absent in multiple myeloma, from diagnosis through maintenance therapy. We explore these provocative and counterintuitive findings arising from profiling of blood and marrow samples.Featured Articles:Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosisA controlled trial for preventing priapism in sickle cell anemia: hydroxyurea plus placebo vs hydroxyurea plus tadalafilHallmarks of T-cell exhaustion and antigen experience are absent in multiple myeloma from diagnosis to maintenance therapy

Today's guest is Dr. Cindy Howard, board certified chiropractic internist and nutritionist, incredible public speaker, award-winning author, and Hodgkin's Lymphoma survivor. Dr. Cindy loves to inspire with humor, wisdom, and finding joy in adversity.We talk so much about joy, especially in the little things, reframing negativity while acknowledging the reality of our situations, bad moments vs. a bad life, finding the quiet, and so much more. Resources:Order Cindy's Book on Amazon: Positively Altered: Finding Happiness at the Bottom of a Chemo BagCindy's Website: https://drcindyspeaks.com/All things Dr. Cindy: https://linktr.ee/drcindyspeaksFollow:Follow me: https://www.instagram.com/melissagrosboll/My website: https://melissagrosboll.comEmail me: drmelissagrosboll@gmail.com

Omg Bravo Bosses! I interviewed Jared Lipscomb from The Valley and so we are skipping our typical reality roundup up today in favor of this interview which was chock FULL OF TEA! You can watch this episode on YouTube! If you don't know Jared, you're about to. Jared started off as the makeup artist for the Vandercrew and became a stable fixture in the lives of the cast members as they progressed to The Valley. Since Jared has been around for many years, he knows the truth about our favorite Bravo stars that we love to hate and he's ready to TELL ALL! We talked about Zach's demonic words that couldn't be said on tv, why he is furious at some cast members for being in the comments, what Dark Side Danny REALLY looks like as well as where the fans have it wrong about Janet. We also get into Jared's fascinating backstory in drag and in makeup, we talk about his cancer journey and lastly, Jared tells the story of how he was integrally involved in Britney Spears' conservatorship battle! Follow Jared on IG @jaredlips and Listen to This Side of the Hill wherever you get your podcasts! For more information on participation in and donations for Leukemia and Lymphoma follow: @llsusa and @nmdp_org Thank you to our SPONSORS! ⁠⁠⁠Petscosset ⁠⁠⁠- Use code: GS15 for 15% off any product! Doodle - Doodle is a user-friendly scheduling platform that helps individuals and teams easily find meeting times, book appointments, and organize events. For a limited time, get 20% off here with CODE: AFFILIATE-20. Rubbish Home - Rubbish makes garbage bags that make trash less day less painful and more enjoyable.We've made your garbage bag dreams come true with our 13-gallon trash bags. Each box includes a fun saying and a reminder when you're low on garbage bags. Our compostable, non-toxic, and PFAS-free trash bags break down quickly and 10% of our garbage bags go to charity. Rubbish does everything your current garbage bags don't! You can purchase my new RE-BRANDED The Bravo Investigator Merch ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠!  Subscribe to Hurrdat Entertainment's ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube Channel⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ for full length video episodes!  Follow me on Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@thebravoinvestigator⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Follow me on Tik Tok: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@thebravoinvestigator⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  Email me your questions or suggestions: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Brunchandbravo@gmail.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  This is another Hurrdat Media Production. Hurrdat Media is a podcast network and digital media production company based in Omaha, NE. Find more podcasts on the Hurrdat Media Network by going to HurrdatMedia.com or the Hurrdat Media YouTube channel!  Learn more about your ad choices. Visit megaphone.fm/adchoices

In this week's episode, we'll learn more about social determinants of health that impact access to allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia, or AML; use of megakaryocyte growth factor receptor-based stem cell depletion as part of pretransplant conditioning in ex vivo autologous gene therapy; and identification of an eight-protein risk signature as well as a novel single protein biomarker, soluble oncostatin M receptor, for risk stratification in AML.Featured Articles:Social Determinants of Health and Access to Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiacMPL-Based Purification and Depletion of Human Hematopoietic Stem Cells: Implications for Pretransplant ConditioningBlood-Based Proteomic Profiling Identifies OSMR as a Novel Biomarker of AML Outcomes

Dr. John Sweetenham and Dr. Marc Braunstein highlight top research on hematologic malignancies from the 2025 ASCO Annual Meeting, including abstracts on newly diagnosed chronic phase CML, relapsed B-cell lymphoma, and multiple myeloma. Transcript Dr. John Sweetenham: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. John Sweetenham. On today's episode, we'll be discussing promising advances in newly diagnosed chronic phase CML, relapsed B-cell lymphoma, multiple myeloma, and other hematologic malignancies that were presented at the 2025 ASCO Annual Meeting. Joining me for this discussion is Dr. Marc Braunstein, a hematologist and oncologist at the NYU Perlmutter Cancer Center. Our full disclosures are available in the transcript of this episode.  Marc, there were some great studies in the heme space at this year's Annual Meeting, and it's great to have you back on the podcast to highlight some of these advances. Dr. Marc Braunstein: Yes, I agree, John, and thank you so much for inviting me again. It's great to be here.  Dr. John Sweetenham: Let's start out with Abstract 6501. This was a study that reported on the primary endpoint results of the phase 3B ASC4START trial, which assessed asciminib versus nilotinib in newly diagnosed chronic phase CML. And the primary endpoint of this, as you know, was time to treatment discontinuation because of adverse events. Can you give us your insights into this study? Dr. Marc Braunstein: Absolutely. So, like you mentioned, you know, asciminib is an allosteric inhibitor of the BCR-ABL kinase that has activity in CML, and that includes patients with the T315I mutation that confers resistance to first- and second-generation TKIs. So, the ASC4FIRST study, which was published last year in the New England Journal of Medicine, showed superior efficacy of asciminib compared to investigator-selected first- or second-generation TKIs, actually leading to the FDA approval of asciminib in first-line CML. So, the authors of that study presented data at this year's ASCO meeting from the phase 3 ASC4START comparing safety and time to discontinuation due to adverse events of asciminib versus nilotinib, a second-generation TKI. So, 568 patients with newly diagnosed CML were randomized one-to-one to once-daily asciminib or twice-daily nilotinib. So, at a median follow-up of 9.7 months, about 11% in the asciminib group and 17% in the nilotinib group discontinued treatment, with significantly fewer discontinuations with asciminib due to adverse events. There was also a secondary endpoint of major molecular response, which was also better with asciminib. For example, the MR 4.5, which is a deep response, was 2.5% versus 0.4% favoring asciminib by week 12. So, I think in conclusion, these results build on the ASC4FIRST study, making the case for the superior safety and efficacy of asciminib versus other first- or second-generation TKIs in newly diagnosed CML. Dr. John Sweetenham: Thanks, Marc. Do you think this is going to change practice? Dr. Marc Braunstein: I think so. I think there are still some questions to be answered, such as what resistance mutations occur after first-line treatment with asciminib. But I think the sum of these studies really make the case for using asciminib upfront in CML. Dr. John Sweetenham: Okay, great. Thank you. And let's move on to our second abstract. This was Abstract 7015 and was reported from Mass General Hospital. And this was a study in patients with relapsed and refractory diffuse large B-cell lymphoma and reported the 2-year results of the so-called STARGLO study. This is a comparison of glofitamab, a T-cell engaging bispecific antibody, with gemcitabine and oxaliplatin in this group of patients. Can you tell us a little bit about your impressions of this study? Dr. Marc Braunstein: Absolutely. So just for background, the treatment landscape for relapsed/refractory large B-cell lymphoma is expanding, now with two bispecific antibodies targeting CD20 that are approved after two or more lines of therapy. Among these, glofitamab was approved in 2023 based on phase 2 data showing an objective response rate of 52%, with 39% complete responses in relapsed/refractory large B-cell lymphoma patients after a median of three prior lines of therapy. Distinguishing glofitamab from epcoritamab, the other approved bispecific, glofitamab was given for 12 cycles and then stopped. Additionally, when combined with gemcitabine and oxaliplatin in the phase 3 STARGLO study, there was significantly improved overall survival compared to rituximab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory large B-cell lymphoma patients at a median follow-up of 11 months.  The authors of that study published last year in Lancet now present at ASCO this year the 2-year follow-up of the STARGLO study. Two hundred and seventy-four patients with a median of one prior line of therapy were randomized two-to-one to glofitamab plus GemOx versus rituximab plus GemOx, with the primary endpoint of overall survival. Here, the median overall survival was not reached versus 13.5 months, with a median PFS also significantly improved at about 14 months versus 4 months in the control. CRS of note in the glofitamab arm was mostly grade 1 or 2, with only about 2.3% grade 3 events. And three of the four patients had grade 1 or 2 neurotoxicity. So, John, putting this into context, I think it's encouraging that we now have randomized data showing the superiority of a bispecific plus chemotherapy over rituximab plus chemotherapy in transplant-ineligible patients. And while only 8% of the patients in the STARGLO study had prior anti-CD19 CAR T-cell therapy, I think this regimen could be considered in those patients who are ineligible for transplant or CAR T-cell therapy. Dr. John Sweetenham: Yeah, I agree. I think a couple of other compelling numbers to me were the fact that around 55% of these patients were alive at 2 years in the group who'd received glofitamab, and that almost 90% of those having that arm of the study who had a CR at the end of treatment were alive at 12 months. So, clearly, it's an active agent and also a kind of great off-the-shelf fixed-duration alternative in these relapsed and refractory patients. Dr. Marc Braunstein: I agree, and I would also note that the phase 3 SKYGLO study is looking at glofitamab plus Pola-R-CHP versus Pola-R-CHP alone. So, we may even be using these eventually in the first-line setting. Dr. John Sweetenham: Absolutely. Let's stay on the theme of diffuse large B-cell lymphoma and look at one other abstract in that space, which was Abstract 7000. This was a study from the HOVON group in the Netherlands, which looked at the prospective validation of end-of-treatment circulating tumor DNA in the context of a national randomized trial. What are your thoughts on this? Dr. Marc Braunstein: So, non-invasive liquid biopsies to detect and monitor cancers via circulating tumor-derived DNA or ctDNA, you know, is really emerging as a valuable tool in both solid and liquid tumors to understand disease biology, and also for drug development. So, to date, the most established application of ctDNA in lymphoma, I would say, is really for monitoring of minimal residual disease. So, in this correlative study by Steven Wang and colleagues in the HOVON group, they evaluated the prognostic significance of MRD status as assessed by ctDNA following first-line treatment with curative intent with either R-CHOP or dose-adjusted R-EPOCH. At the end of treatment, encouragingly, 76% of patients were MRD-negative, and 24% were MRD-positive. Now, of note, MRD-positive status at the end of treatment predicted inferior progression-free survival at 2 years, with only 28% of patients who are MRD-positive being progression-free versus 88% who are MRD-negative. And in fact, all the patients who failed to achieve a complete response after first-line treatment and were MRD-positive ultimately relapsed. So, circulating tumor cells are rarely found in large B-cell lymphomas, and so this study really builds on accumulating data that ctDNA has clinical value to detect residual disease with a non-invasive approach. So, there are many implications of how we could potentially use this to detect early signs of relapse, to potentially escalate treatment for consolidation if patients remain MRD-positive. So, I think this will eventually become utilized in clinical practice. Dr. John Sweetenham: Yeah, I agree. I think it's interesting that it provided an independent assessment of response, which was independent, in fact, of the results of PET-CT scanning and so on, which I think was very interesting to me. And the authors of the abstract actually commented in their presentation that they think this should be integrated as part of the standard response assessment now for patients with large B-cell lymphoma. Would you agree with that? Dr. Marc Braunstein: I would. For one thing, it allows repeated sampling. It's a non-invasive approach; it doesn't necessarily require a bone marrow biopsy, and it may have more sensitivity than conventional response measures. So, I think having a standardized system to assess ctDNA will be helpful, and definitely, I think this will be a valuable biomarker of disease response. Dr. John Sweetenham: Okay, great. Thanks. We're going to change gear again now, and we're going to highlight two abstracts in the multiple myeloma space. The first one of these is Abstract 7507. And this abstract reported on the long-term results of the CARTITUDE study for patients with relapsed and refractory multiple myeloma. What are your comments on this presentation? Dr. Marc Braunstein: So, this study actually got a lot of press, and I've already had multiple patients asking me about CAR T-cells as a result. Just as some background, CAR T-cells targeting BCMA, which is pretty much universally expressed on malignant plasma cells in myeloma, have really shown remarkable responses, especially in heavily pretreated patients, showing superior progression-free survival in both later and earlier phases of the disease, including in randomized studies in patients with second-line or beyond. So, the CARTITUDE-1 was really the original Phase 1/2 study of ciltacabtagene autoleucel, one of the two approved anti-BCMA CAR T-cell products, which was investigated in patients with a median of six to seven prior lines of therapy. So, these were patients who were pretty heavily pretreated. So, in the study presented by Voorhees at this year's ASCO meeting, this was the long-term follow-up at a median of 5 years from the one-time CAR infusion in these patients with a median of five prior lines of therapy. And remarkably, of the 97 patients, 33% remained progression-free at 5 years plus, without needing any further myeloma treatment during that time. And among those 33% of patients, 23% had high-risk cytogenetics, which we know are notoriously difficult to achieve responses in. What was interesting that they presented as correlative studies was there were some biomarkers that were distinguishing the patients who had the long PFS, including enrichment of more naive T-cells in the product, lower neutrophil-to-T-cell ratio, higher hemoglobin and platelets at baseline, and higher CAR T-cell levels relative to soluble BCMA levels. And the fact that they reported a median overall survival of 61 months in these really heavily pretreated patients, I think these data are impressive. I think we're going to continue to be using CAR T even earlier in the disease status than fifth or sixth line, as it was studied in CARTITUDE-1. There are even ongoing studies looking at first-line treatment with CAR T-cells. Dr. John Sweetenham: So, do you think that those 33% of patients who are disease-free at 5 years, do you think any of those are cured?  Dr. Marc Braunstein: That was one of the headlines in the press. I think if we're going to discuss things like "operational cures," where we're transforming myeloma into really a chronic disease, where patients can live practically a normal life expectancy, I think the measure of 5 years, especially in this population that was explored in CARTITUDE-1, I think we can call that close to a cure. Dr. John Sweetenham: Okay. Well, thank you. Exciting data, for sure. We're going to conclude today with another abstract in the multiple myeloma space. And this was Abstract 7500, which looked at an MRD, minimal residual disease-driven strategy following induction and transplant-eligible newly diagnosed multiple myeloma patients and reported on the primary endpoints of the phase 3 MIDAS trial. Can you walk us through this one, Marc? Dr. Marc Braunstein: Absolutely. It is a bit more complicated than the prior one we discussed because this is a randomized study with four arms. So, I'll start by saying that anti-CD38-based quadruplet regimens continue to show superior outcomes in both transplant-eligible and -ineligible newly diagnosed multiple myeloma patients. The MIDAS study mentioned is an open-label phase 3 trial with four arms in transplant-eligible newly diagnosed myeloma patients.  And initially, these patients were all treated with quadruplet therapy with the anti-CD38 antibody isatuximab combined with carfilzomib, lenalidomide, and dexamethasone in 718 newly diagnosed myeloma patients. So, they received the quadruplet regimen for six cycles and then were randomized based on their MRD status at 10 to the negative fifth following six cycles of induction. And that first randomization, if they were MRD-negative, was to either consolidation with six more cycles of the quadruplet regimen or transplant, autologous transplant, plus two cycles additionally of the quadruplet regimen. And both arms were followed by lenalidomide maintenance. The primary endpoint was MRD negativity at 10 to the negative sixth prior to entering the lenalidomide maintenance component. And in addition, the patients who were MRD-positive after induction were randomized to transplant plus two cycles of consolidation or a tandem autologous transplant. So, the median follow-up of the study was about 16 months, and the pre-maintenance rate of MRD negativity was high, between 84 to 86% between the two arms who were MRD-negative, which was not significantly different. And as far as the 233 patients who were MRD-positive, the pre-maintenance MRD negativity was also not significantly different at 40% for those who received autologous transplant, and 32% who received a tandem transplant. So, there's a lot of debate in the myeloma field about the evolving role of autologous transplant and whether transplant still plays a significant role in patients who are either MRD-negative after induction or who have deep remissions and are of standard risk. So, I think these data suggest that patients who are MRD-negative after induction with a quadruplet regimen studied here, which was Isa-KRd, plus consolidation, may possibly be able to forego consolidation with autologous transplant. And likewise, for those patients who are MRD-positive after induction, tandem transplant didn't seem to provide much of a benefit compared to single transplant, which is consistent with prior studies such as the StaMINA study. Dr. John Sweetenham: So, where do you think this leaves us, Marc? Are we going to need more studies before we have any definitive guidance on whether an autologous transplant is still appropriate for those patients who are MRD-negative? Dr. Marc Braunstein: Well, as clinicians, we want to do what's best for our patient. And in myeloma, the best we can do is to get as deep remissions as possible, meaning MRD negativity. And so, I think it's clear from the MIDAS study and others that quadruplet regimens provide the deepest remissions when given upfront. We can debate the role of autologous transplant. I think certainly the role of tandem autologous transplant is fading. But as far as a single autologous transplant as consolidation, I think it's reasonable as a goal to try to achieve MRD negativity after the transplant, especially for patients who remain MRD-positive after induction. Dr. John Sweetenham: Okay, great. Marc, thanks as always for sharing your insights on the heme malignancies studies from the ASCO meeting this year and for joining us on the ASCO Daily News Podcast. Always appreciate hearing your thoughtful and balanced input on these. Dr. Marc Braunstein: My pleasure. Thank you, John. Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's guest:  Dr. John Sweetenham Dr. Marc Braunstein   @docbraunstein     Follow ASCO on social media:   @ASCO on Twitter  ASCO on Bluesky  ASCO on Facebook   ASCO on LinkedIn     Disclosures:  Dr. John Sweetenham:  Consulting or Advisory Role: EMA Wellness  Dr. Marc Braunstein:  Consulting or Advisory Role: Pfizer, Bristol-Myers Squibb/Celgene, Adaptive Biotechnologies, GlaxoSmithKline, ADC Therapeutics, Janssen Oncology, Abbvie, Guidepoint Global, Epizyme, Sanofi, CTI BioPharma Corp  Speakers' Bureau: Janssen Oncology  Research Funding (Institution): Janssen, Celgene/BMS

In a heartfelt conversation, Def Leppard guitarist Vivian Campbell reveals his remarkable path to beating cancer through a successful bone marrow transplant. He discusses his 13-year battle with Hodgkin's Lymphoma, the emotional impact of finding a perfect donor match, and his unwavering determination to keep performing throughout treatment. Campbell also shares updates on Def Leppard's upcoming album, his side project Last in Line, and his newfound passion for rally racing. Also on the podcast, from writing 'New York Groove' on a flight to NYC to seeing The Beatles adopt his tailor recommendations, Russ Ballard opens up about his remarkable 60-year career crafting hits for rock's biggest names. He reveals the origins of classics like 'Since You've Been Gone' and 'God Gave Rock and Roll to You,' while discussing his latest double album and philosophy that keeping active in music helps maintain youthful energy.  Catch Eddie Trunk every M-F from 3:00-5:00pm ET on Trunk Nation on SiriusXM Faction Talk Channel 103.And don't forget to follow Eddie on Twitter and Instagram!Follow the link to get your free 3-month trial of SiriusXM: http://siriusxm.com/eddietrunk Find all episodes of Trunk Nation: https://siriusxm.com/trunknation

In today's episode, we had the pleasure of speaking with Alexey Danilov, MD, PhD, about current challenges and emerging treatment approaches for the management of leukemia and lymphoma that were published in a manuscript based on proceedings from the inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference. Dr Danilov is the Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, medical director of the Early Phase Therapeutics Program for the Systems Clinical Trials Office, co-director of the Toni Stephenson Lymphoma Center, and a professor in the Division of Lymphoma in the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California. In our exclusive interview, Dr Danilov highlighted recent advances and controversies in the treatment of select patients with hematologic malignancies. He noted chemotherapy-free regimens that are shifting treatment paradigms in mantle cell lymphoma, preferred and emerging BTK inhibitors for the management of chronic lymphocytic leukemia, and the evolution of CD19-directed CAR T-cell therapies for diffuse large B-cell lymphoma. Dr Danilov concluded by taking a forward glance at future developments like BTK degraders and novel CAR T-cell therapy targets.

Blood editor Dr. Laurie Sehn discusses the topic of "Aggressive non-Hodgkin lymphoma: defining and managing high-risk subsets" featuring Drs. Mark Roschewski, Grzegorz Nowakowski, and Neha Mehta-Shah, who each contributed to the articles featured in the review series on high-risk aggressive lymphoma.See the full review series on high risk lymphoma in volume 144, issue 25 of Blood.

In this week's episode, we' ll learn about how TET3 has a key role in GVHD. In mice, a deficiency of Tet3 in donor T cells inhibited pathogenic immunoglobulin class switching and suppressed lung fibrosis. Accordingly, TET3 may be a new therapeutic target in chronic GVHD. After that: rilzabrutinib, a BTK inhibitor for ITP. In a randomized, placebo-controlled trial, treatment produced rapid and durable platelet responses, with acceptable safety, in adults with immune thrombocytopenia who had failed multiple previous therapies. Finally: exploring pre-TCR surface expression patterns in T-cell ALL. Co-inhibition of the interleukin-7 receptor and pre-T cell receptor pathways may play a therapeutic role for a subset of T-lymphoblastic leukemias.Featured Articles: Deficiency of T follicular helper cell Tet3 DNA demethylation inhibits pathogenic IgG2c class switching and chronic GVHDSafety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 studySurface pTα expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL

Valerie David, also known as The Pink Hulk, is a three-time cancer survivor (non-Hodgkin's lymphoma, stage 2 breast cancer, and stage 4 metastatic breast cancer) who turned her journey of resilience into an award-winning one-woman show. Through humor, raw honesty, and advocacy, she inspires audiences worldwide—proving that even cancer won't stop her from taking center stage.Check out Valerie's show, The Pink Hulk here: https://pinkhulkplay.comKey Highlights:- Valerie trusted her inner voice when symptoms appeared, even when doctors initially dismissed them. If you are able to get second opinions, advocate for yourself, and listen to your gut, you'll find this to be useful in other parts of your own life.- Balancing intuition with fear over symptoms can be tricky, but Valerie advises: don't panic over nothing, don't choose to live in fear. Instead, stay proactive by communicating with your care team about any arising symptoms.About our guest:Valerie David is an actor, playwright, writer and editor. Her greatest accomplishment in life is being a three-time cancer survivor. She was diagnosed and treated for Stage III Non-Hodgkin's Lymphoma in 1999, Stage II Breast Cancer in 2014 and 2015, and Stage IV Breast Cancer in 2018. As of April 2019, she has beaten cancer again! Valerie reactivated her superhero within, and exactly 5 months after receiving hormone treatment only in pill form–no surgery, no radiation, no chemotherapy, Valerie no longer has active disease. She has since kept up a full schedule of performances–nothing has stopped her. Valerie's inspirational solo show, The Pink Hulk, has been accepted into almost 50 different play festivals worldwide since its 2016 debut, won multiple awards and has been touring since its very first performance, impacting audiences with the show's universal message of hope and empowerment. She has performed in over 25 different cities and globally, including in England, Sweden, Iceland, and Finland. A graduate of the American Academy of Dramatic Arts, her credits include the Off-Broadway production of A Stoop on Orchard Street, Cookie in Rumors and Claudia Shear's Blown Sideways Through Life. Films: How I Became that Jewish Guy, which premiered at a November 2015 NYC Film Festival, and Bridges and Tunnels. Valerie volunteers as a motivational speaker at the Leukemia & Lymphoma Society's Team in Training events and Make-A-Wish Foundation. As a marathon cyclist, she co-founded Cycle of Hope, which raises money for national and international cancer organizations through bike marathons. Her most recent biking event raised almost $5,000 for the American Cancer Society and the Leukemia & Lymphoma Society.Key Moments:At 7 minutes 28 seconds “What is my choice? Is my choice going to live in fear every single day? Is it going to be well, we'll deal with it when it happens. So I think what I've learned from cancer is don't worry until there's something to worry about.”Disclaimer: All content and information provided in connection with Manta Cares is solely intended for informational and educational purposes only. This content and information is not intended to be a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until May 27, 2026.Planting Roots for Next-Gen Bispecific Antibodies in Hematologic Cancers: Collaborative Principles to Extend the Reach of Immunotherapy in Myeloma and Lymphoma In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until May 27, 2026.Planting Roots for Next-Gen Bispecific Antibodies in Hematologic Cancers: Collaborative Principles to Extend the Reach of Immunotherapy in Myeloma and Lymphoma In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until May 27, 2026.Planting Roots for Next-Gen Bispecific Antibodies in Hematologic Cancers: Collaborative Principles to Extend the Reach of Immunotherapy in Myeloma and Lymphoma In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until May 27, 2026.Planting Roots for Next-Gen Bispecific Antibodies in Hematologic Cancers: Collaborative Principles to Extend the Reach of Immunotherapy in Myeloma and Lymphoma In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/PJA865. CME/MOC/NCPD/AAPA/IPCE credit will be available until May 27, 2026.Planting Roots for Next-Gen Bispecific Antibodies in Hematologic Cancers: Collaborative Principles to Extend the Reach of Immunotherapy in Myeloma and Lymphoma In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

In this special episode, Dr. Shaji Kumar from the Mayo Clinic speaks with Blood editor Dr. Laurie Sehn on a paper recently published in Blood, "Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma". The findings demonstrate eliminating the need for sequential confirmation of response in multiple myeloma. The study, involving 583 episodes of progression, found that simultaneous confirmation of disease progression using two different markers (e.g., serum protein electrophoresis and serum free light chain assay) was 98% accurate, compared to 82% for sequential confirmation. This suggests that simultaneous confirmation could improve clinical trial accuracy and reduce false censoring. The International Myeloma Working Group is set to revise its response criteria to incorporate these findings, potentially simplifying disease assessment and reducing the need for multiple blood draws.

In this week's episode, we'll learn more about the identification and characterization of stem cell-like leukemia blasts using single cell multi-omics, cyclophosphamide as a treatment for non-immune effector cell-associated neurotoxicity in patients treated with B-cell maturation antigen, or BCMA, targeted CAR T-cell therapies, and how differences in glycosylation affect the clearance of human plasma-derived and recombinant von Willebrand factor concentrates.Featured Articles:Single-cell panleukemia signatures of HSPC-like blasts predict drug response and clinical outcomeCyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatmentEnhanced α2-3–linked sialylation determines the extended half-life of CHO-rVWF

In this How I Treat Series episode Dr. Thomas Ortel leads a discussion with author Dr. Patrick Foy on his paper “How I diagnose and treat thrombocytopenia in geriatric patients”. See the full How I Treat series on geriatric hematology in volume 143 issue 3 of Blood Journal.

Mike is out of town, so Jim brought in one of Third Street Barbell's most consistent and inspirational members, Josh Hajar.Josh is an emergency department nurse who faced a harrowing fight with non-Hodgkin's Lymphoma, and then suffered an injury that set back his recovery and fitness goals. When he arrived at Third Street, he was finally ready to execute a winning game plan for losing weight and getting stronger. Building on the advice he received when he first received his cancer diagnosis to “Be Positive,” Josh sets a strong example in and out of the gym.Join our Discord for free at goodcompanydiscord.com!Check out our gym (Third Street Barbell) at ThirdStreetBarbell.com https://www.thirdstreetbarbell.com/ and subscribe for updates about our apparel line at goodcompanyapparel.com https://3sb.co/! Local memberships and international fresh fits! Get early access to our NEXT DROP!Check out our podcast website: 50percentfacts.com https://www.50percentfacts.com/50% Facts is a Spreaker Prime podcast on OCN – the Obscure Celebrity Network.____Hosted by Mike Farr (@silentmikke) https://www.instagram.com/silentmikke/ and Jim McDonald (@thejimmcd). https://www.instagram.com/thejimmcd/Produced by Jim McDonaldProduction assistance by Sam McDonald and Sebastian Brambila.Theme by Aaron Moore. Show art by Joseph Manzo (@jmanzo523)Become a supporter of this podcast: https://www.spreaker.com/podcast/50-facts-with-silent-mike-jim-mcd--5538735/support.

Today on The Hormone Genius Podcast, we are so excited to welcome Maddy Pollack—a passionate Integrative Nutrition Health Coach, Hormone Health Coach, and Yoga Instructor who specializes in helping women take control of their menstrual and hormonal health naturally. Maddy's journey is incredibly powerful. At just 24 years old, she was diagnosed with Stage 2 Hodgkin's Lymphoma. That life-altering experience sparked a deep curiosity and commitment to understanding the why behind her illness—and ultimately led her to uncover the often-overlooked connection between nutrition, hormone balance, and emotional wellness. Now fully in remission, Maddy dedicates her work to guiding women in naturally reducing PMS symptoms, balancing their hormones, releasing stubborn weight, and reconnecting with their bodies—without relying on medication. In our conversation today, we dive into: The missing link between traditional medical treatment and nutritional healing How to naturally regulate your cycle and ease PMS, and heal from PCOS The impact of stress, gut health, and lifestyle on hormone function Practical, empowering tips for working with your cycle instead of against it Maddy brings a compassionate, science-informed approach to wellness, and I know our listeners are going to walk away with so many actionable insights.

Primary Central Nervous System Lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma that affects the brain, spinal cord, or… The post Breaking Down Primary CNS Lymphoma: From Rare Diagnosis to Growing Progress first appeared on The Bloodline with LLS.

In this week's episode, we'll hear about new insights into PU.1-mutated agammaglobulinemia. Researchers show that haploinsufficiency of the master transcriptional regulator PU.1 causes agammaglobulinemia and dendritic cell deficiencies. These patients experience an array of infectious and non-infectious complications, but not leukemia. After that: venetoclax-based induction therapy in younger patients with AML. Venetoclax plus decitabine was associated with superior safety and non-inferior response rates compared to intensive chemotherapy. Is it time to consider lower-intensity therapy beyond older and unfit patients? Finally, a focus on venous thromboembolism. Researchers link BGAT, an enzyme pivotal to determining blood type, to risk of future VTE. They say high plasma levels of BGAT contribute to risk above and beyond what can be explained by von Willebrand factor and Factor VIII.Featured Articles:One hundred thirty-four germ line PU.1 variants and the agammaglobulinemic patients carrying themVenetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AMLHisto–blood group ABO system transferase plasma levels and risk of future venous thromboembolism: the HUNT study

Dr. Doug Thamm discusses the development and use of Tanovea, a drug for treating lymphoma in dogs. He explains the drug's origins, initially researched as a human cancer therapeutic in collaboration with Gilead Sciences, and its transition to veterinary use.   Dr. Thamm provides insights into Tanovea's application, dosage, and effectiveness compared to the CHOP protocol, as well as its potential side effects and other possible uses in different cancer types like multiple myeloma. The episode also delves into related immunotherapy research and personal reflections from Dr. Thamm, a double cancer survivor, on his career choice in veterinary oncology. Your Voice Matters!   If you have a question for our team, or if you want to share your own hopeful dog cancer story, we want to hear from you! Go to https://www.dogcancer.com/ask to submit your question or story, or call our Listener Line at +1 808-868-3200 to leave a question. Related Videos:  https://www.youtube.com/watch?v=G0iRyKshzq8  Related Links:  Our article on lymphoma: https://www.dogcancer.com/articles/types-of-dog-cancer/lymphoma-in-dogs/  Our article on Tanovea: https://www.dogcancer.com/articles/drugs/tanovea-rabacfosadine-chemotherapy/  Get the facts on dog cancer remission: https://www.dogcancer.com/articles/stats-and-facts/dog-cancer-remission/  Chapters:  00:00 Introduction  00:13 Interview with Dr. Doug Thamm  00:26 The Early Involvement with Tanovea  00:41 Challenges and Discoveries in Drug Development  02:16 Transition from Human to Veterinary Use  02:48 Clinical Trials and Dosage Experiments  06:45 FDA Approval and Practical Use  08:05 Comparing Tanovea and CHOP Protocol  15:23 Exploring Alternative Treatments: Laverdia  18:43 Off-Label Uses and Future Research  23:46 Exploring Tanovea's Effectiveness in Blood Cancers  25:14 Cost Comparison: Tanovea vs. CHOP  26:15 Side Effects of Tanovea  28:47 Pulmonary Fibrosis and Breed-Specific Risks  32:52 Personal Cancer Journeys: Dr. Doug and His Wife  38:23 Debunking Myths About Dog Cancer Treatment  42:24 The Future of Cancer Treatment: Immunotherapy  45:23 Conclusion and Resources    Get to know Dr. Doug Thamm: https://www.dogcancer.com/people/doug-Thammm-v-m-d-diplomate-acvim-oncology/   For more details, articles, podcast episodes, and quality education, go to the episode page: https://www.dogcancer.com/podcast/   Learn more about your ad choices. Visit megaphone.fm/adchoices

In this week's episode we'll learn about how frequent blood donation affects clonal hematopoiesis in older, male blood donors; the effect of immune microenvironment on response to bispecific antibodies in diffuse large B-cell lymphoma; and the feasibility of adding blinatumomab to early consolidation therapy in CD19-positive Ph-negative B-cell acute lymphoblastic lymphoma.Featured ArticlesClonal Hematopoiesis Landscape in Frequent Blood DonorsIntegrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody responseUpfront Blinatumomab Improves MRD Clearance and Outcome in Adult Ph-negative B-lineage ALL: The GIMEMA LAL2317 Phase 2 Study

In part two of the How I Treat Series on Transfusion Medicine Dr. Erica Wood interviews the "How I Manage Major Hemorrhage" author group: Drs. Jeannie Callium, Keyvan Karkouti, and Ron George.Find the full published review series in Volume 145 Issue 20 of Blood Journal.

BUFFALO, NY – May 19, 2025 – A new #research paper was #published in Volume 16 of Oncotarget on May 9, 2025, titled “Analytical validation of a circulating tumor DNA assay using PhasED-Seq technology for detecting residual disease in B-cell malignancies.” In this study, a team from Foresight Diagnostics led by first author Nina Klimova and corresponding author Laura Hyland validated a new DNA-based blood test designed to detect minimal residual disease (MRD) in patients with B-cell cancers. This assay uses a highly sensitive method called Phased Variant Enrichment and Detection Sequencing (PhasED-Seq) to find tiny fragments of tumor DNA in the blood. Its ultra-sensitive detection capabilities offer a powerful tool for early cancer detection, monitoring treatment response, and predicting cancer reappearance. B-cell lymphomas, such as diffuse large B-cell lymphoma (DLBCL), are among the most prevalent blood cancers. Although many patients respond to initial treatment, up to 40% relapse. Standard monitoring methods such as imaging scans often miss low levels of cancer cells, creating a need for more precise tools. This study introduces a non-invasive blood test that improves the detection of MRD, a critical factor in guiding follow-up care and early intervention. The test works by tracking unique groups of mutations known as phased variants in tumor DNA. These mutations are more specific to cancer and allow for highly accurate identification of tumor fragments in the bloodstream. The PhasED-Seq-based MRD assay was tested on three types of samples. First, blood plasma from healthy individuals was used to confirm the test does not give false positives. Second, researchers created controlled samples by mixing tumor DNA from lymphoma patients with healthy DNA to measure how sensitive and precise the test is. Finally, blood samples from patients with B-cell lymphoma were used to compare the new test to an existing method. Across all sample types, the PhasED-Seq-based MRD assay demonstrated exceptional performance—capable of detecting fewer than one cancer DNA molecule per million normal DNA fragments. It also demonstrated a very low false positive rate and over 96% reproducibility across different laboratory conditions. Compared to an existing method, the new PhasED-Seq assay showed more than 90% agreement in positive results and nearly 78% agreement in negative results. In cases where the tests disagreed, the new method aligned more closely with actual clinical outcomes, including whether patients relapsed or stayed in remission. “The background error rate of the PhasED-Seq-based MRD assay was 1.95E-08, or 1.95 mutant molecules in 100 million informative molecules.” The findings support the use of PhasED-Seq-based MRD assays in routine clinical practice. It could be especially useful for identifying patients who need additional treatment even when imaging results appear normal. This aligns with updated clinical guidelines that encourage the use of blood-based DNA tests to supplement traditional scans in lymphoma care. This study offers strong evidence that the PhasED-Seq-based MRD assay is a precise, reliable, and clinically relevant tool. By detecting signs of cancer earlier and more accurately, it may help clinicians tailor treatments to individual patients and improve long-term outcomes in B-cell malignancies. DOI - https://doi.org/10.18632/oncotarget.28719 Correspondence to - Laura Hyland - laura.hyland@foresight-dx.com Video short - https://www.youtube.com/watch?v=8hdh3G5zvlc Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

In this week's episode, we'll learn about stopping myeloma maintenance therapy in the modern era. New research suggests that many patients in remission can discontinue lenalidomide, remaining treatment-free, without jeopardizing disease response. After that: a novel congenital neutropenia syndrome. Mutations in the COPZ1 gene impact myeloid differentiation and development of neutropenia. Researchers describe the mechanisms and propose a treatment strategy for restoring granulopoiesis. Finally, ruxolitinib maintenance therapy after allogeneic transplant. In a phase 2 study, this treatment strategy was associated with low rates of chronic graft-versus-host disease. Investigators say the use of JAK inhibitors in this context warrants further study.Featured Articles: Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myelomaA new severe congenital neutropenia syndrome associated with autosomal recessive COPZ1 mutationsLow rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT

In this two-part series, Dr. Erica Wood talks with Drs. Masja de Haas, Helen Savoia, and Stella Chou about their articles in the How I Treat Series on Transfusion Medicine. Topics include noninvasive prenatal testing for red blood cell and platelet antigens, transfusion cases in sickle cell disease, and pregnant patients who are alloimmunized to RBC antigens. Find the full published review series in Volume 145 Issue 20 of Blood Journal.

In this deeply personal episode, Drs. Samantha and Samuel Siegel share their journey of navigating cancer, medical school, and family life together. From their time as medical students at Jefferson Medical College to the challenges they faced with Samuel's testicular cancer diagnosis and Samantha's battle with Hodgkin's Lymphoma, their story highlights the complexities of being both physicians and patients. Throughout their experiences, they uncovered significant gaps in cancer survivorship care, prompting them to become passionate advocates for change in the healthcare system.Join Samantha and Samuel as they discuss the struggles and triumphs of parenting through illness, managing health crises while continuing their careers, and the emotional toll of caring for one another. With their shared mission to improve survivorship care and elevate its importance within medical practice, this episode serves as an inspiring and thought-provoking conversation on resilience, advocacy, and the power of personal stories in driving change.About Our Guest:Samuel Siegel, MDPediatricianDignity Health Woodland ClinicSamuel Siegel is a general pediatrician in Woodland, CA serving a predominantly rural population, including immigrants from Mexico and Central America. He practices hospital medicine, seeing newborns during their birth hospitalization and he attends high risk deliveries.In his outpatient practice, Dr. Siegel has a special interest in pediatric obesity and nutrition and founded an annual healthy eating project called Home-Grown Health. There, he gives away 1000 vegetable starts, soil, and fertilizer each year to families in his community. He believes that allowing children to participate in the unique process of nurturing plants from seeds will more successfully promote healthy eating habits.He is also a patient who has learned to live a fulfilling life with chronic medical conditions since his early twenties including inflammatory bowel disease, treatment for cancer while in medical school, and a living donor liver transplant from his brother in 2016. He is a husband and partner to a physician-patient spouse and together they have three wonderful children.

In a conversation with CancerNetwork®, Viviana Cortiana, MS4, medical student in the Department of Medical and Surgical Sciences at the University of Bologna, and Yan Leyfman, MD, a resident physician from the Icahn School of Medicine of the Mount Sinai Health System, discussed their publication in the March 2025 issue of ONCOLOGY titled “Expanding horizons in T-cell lymphoma therapy: a focus on personalized treatment strategies.” Throughout the discussion, the authors spoke about the current lymphoma landscape, CAR T-cell therapy, and the evolving understanding of the tumor microenvironment. Specifically, Cortiana covered a shift from histology-based classification to molecular tumor type classification using next-generation sequencing, as well as a growing interest in biomarker-driven therapies. Regarding the limited efficacy of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) in T-cell lymphoma, she listed potential advances in combination therapies for angioimmunoblastic T-cell lymphoma (AITL), which include combining P13K and HDAC inhibition as well as CD30- and TRBC1-targeting CAR T-cell therapies. Furthermore, Leyfman discussed strategies that “reprogram” the microenvironment to address malignant T cells, particularly through epigenetic and adoptive cell therapies. Leyfman concluded by discussing future implications for T-cell lymphoma treatment, emphasizing an emergence of precision medicines and armored CAR engineering strategies. Authors of the manuscript published in ONCOLOGY outlined the available treatment options for peripheral T-cell lymphoma (PTCL), which include targeted therapies through EZH2 inhibition, chemotherapy with CHOP, CAR T-cell therapies, and allogenic stem cell transplantation. Additionally, they highlighted encouraging results from clinical trials evaluating epigenetic-targeted therapies through the identification of molecular aberrations, which can help tailor treatments to individual patients.  Furthermore, the article explored limitations of chemotherapy as well as autologous stem cell transplantation (ASCT), which may not be feasible for older patients or those with comorbidities. Authors suggested that targeted therapies may enhance tumor specificity while reducing systemic toxicity. Given the risks associated with ASCT, they emphaisized a focus on the incorporation of optimized treatment strategies, such as novel pharmaceuticals and combination therapies, into clinical practice for patients with PTCL.

In this week's episode, we'll learn more about how measurable residual disease might help guide decisions about post-transplant gilteritinib maintenance in FLT3-ITD acute myeloid leukemia, or AML; how stemness contributes to chemotherapy resistance in AML; and effects of babesiosis on red blood cells from individuals with sickle cell disease, sickle cell trait, and wild-type hemoglobin. Featured Articles:Measurable residual disease and post-transplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML GATA2 links stemness to chemotherapy resistance in acute myeloid leukemia Babesiosis and Sickle Red Blood Cells: Loss of Deformability, Heightened Osmotic fragility and Hyper-vesiculation 

- Overview of Diffuse Large B-Cell Lymphoma - Staging & Grading - Current Standard of Care - Treatment Options for Resistant Disease - New & Emerging Treatment Approaches - The Role of Clinical Trials - How Research Contributes to Treatment Choices - Tips to Manage Treatment Side Effects, Symptoms, Discomfort & Pain - The Increasing Role of Telehealth/Telemedicine Appointments - Key Questions to Ask Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Questions to Ask Our Panel of Experts

Find your Human Design variables for FREE here → https://www.vanesshenry.com/variable-calculator    Human Design shows us that we're each here to show up and operate differently energetically – in personality, relationships, work – but did you know that it affects how we show up physically, too?   Your Human Design variables tend to play a big role in why your body shows up the way it does when it comes to your health.   They can help you understand why you tend to have certain symptoms and issues… and how you can heal them in a way that will work for YOU.   Today, we get to hear all about it from my ~absolute favorite~ person to learn variable from, Vaness Henry! Vaness is a 6/2 ego manifestor, shamanic healer, writer, and cancer survivor. She's also an expert on the variables, and how they affect our health and wellbeing.   In the episode, we talked about…  Vaness's story: Getting diagnosed with Hodgkin's Lymphoma at 16, finding Human Design, and using her chart to understand her cancer experience The patterns between HD charts and chronic illness that Vaness has discovered (don't worry, this DOES NOT MEAN you will get sick!) Top 3 variable aspects to look at if you want to understand your symptoms, especially if they're chronic or just not going away Why a “healthy environment” is waaaaay more than location or your physical surroundings How your natural archetypes, personality, and energy play into your health (or lack of health) Vaness's solution for those who don't know their exact birth time, but still really want to play around with variable  Examples from both our charts, of course  

Enjoy a replay of Monday night's Patriots post-draft party co-hosted by Andrew and the Boston Herald's Doug Kyed. Together, they interview ESPN's Mina Kimes, Jason McCourty, Danny Kelly, Danny Heifetz, Phil Perry, Mike Giardi, Taylor Kyles, Michael Hurley, Sam Monson and Steve Palazzolo all about the Patriots draft and potential for next season. Donate at https://princesshallieforever.com — all proceeds go to Doug Kyed's Leukemia and Lymphoma fundraiser in honor of his daughter, Hallie. Pats Interference is presented by: Gametime! Take the guesswork out of buying NFL tickets with Gametime. Download the Gametime app, create an account, and use code CLNS for $20 off your first purchase. Download Gametime today. What time is it? Gametime! Terms apply. Go to ⁠⁠https://gametime.co⁠⁠ ! Learn more about your ad choices. Visit megaphone.fm/adchoices

In this week's episode, we'll hear about how researchers look toward the lung, and find uniquely programmed blood stem cells. This study is the first to fully characterize hematopoietic stem and progenitor cells in the adult human lung. After that: researchers develop a neural network-based probabilistic classifier, DLBclass, that assigns all diffuse large B-cell lymphomas into one of five genetic subtypes. It's an inclusive taxonomy that they say provides actionable genetic information in almost all patients with DLBCL. Finally, new insights on NETS, or neutrophil extracellular traps. In the liver vasculature, NET removal leads to secondary inflammation, resulting in new waves of NETS that may impact future infection. We'll review these and other findings from this recent mouse model study.Featured Articles:Decoding functional hematopoietic progenitor cells in the adult human lungDLBclass: a probabilistic molecular classifier to guide clinical investigation and practice in diffuse large B-cell lymphomaDonor regulatory T-cell therapy to prevent graft-versus-host disease

In this week's episode we'll learn more about how phosphoseryl-tRNA kinase inhibition promotes cell death in acute myeloid leukemia, or AML; APOE gene variants and their association with post-hematopoietic stem cell transplant outcomes in AML; and pathways by which chronic inflammation and oxidative stress may lead to cardiomyopathy in patients with sickle cell disease.Featured Articles:PSTK inhibition activates cGAS-STING, precipitating ferroptotic cell death in leukemic stem cells Common Hereditary Variants of the APOE Gene and Posttransplant Outcome in Acute Myeloid Leukemia 17R-Resolvin D1 Protects Against Sickle Cell Related Inflammatory Cardiomyopathy in Humanized Mice 

Featuring an interview with Ms Amy Goodrich, including the following topics: Presentation and management of follicular lymphoma (FL) (0:00) Case: A woman in her late 70s with heavily pretreated disease experiences complete response to mosunetuzumab (24:41) Case: A man in his early 60s with extensive diffuse large B-cell lymphoma and short response to CAR-T is successfully bridged to allogeneic transplant with glofitamab (30:15) Case: A man in his late 50s with transformed FL has limited treatment options due to lack of social support (45:51) Effects of bispecific antibodies in follicular and diffuse large B-cell lymphoma (52:53) NCPD information and select publications

Nurse practitioner Ms Amy Goodrich from The Sidney Kimmel Comprehensive Care Center in Baltimore, Maryland, presents cases from her practice illustrating the efficacy and safety of bispecific antibodies for non-Hodkin lymphoma. NCPD information and select publications here.